ClinicalTrials.gg
RecruitingNCT07563088SPARE-1stUpdated Nov 12, 2026

SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma

An observational study in Adenoid Cystic Carcinoma and Sinonasal Carcinoma, sponsored by Eye & ENT Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Eye & ENT Hospital of Fudan University · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 3, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Carcinoma, Adenoid Cystic with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Carcinoma, Adenoid Cystic · China.

Started
2026
with 4 others
Observational
2 of 14
2 open now
Registered
12th of 14
by date
Lead sponsor
5 of 14
Eye & ENT Hospital of Fudan University

Among the 14 studies in Carcinoma, Adenoid Cystic with a site in China, this one is one of 5 that started in 2026, is one of 2 observational ones, and was the 12th registered.

Carcinoma, Adenoid Cystic

86 studies on the registry are indexed under Carcinoma, Adenoid Cystic; 26 are open to participants now.

Browse Carcinoma, Adenoid Cystic studies →

Open to participants now

7 of the 14 studies in Carcinoma, Adenoid Cystic with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 23 Carcinoma, Adenoid Cystic studies recruiting now, 15 (65%) set no upper age limit and 3 (13%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Carcinoma, Adenoid Cystic with a site in China, or all of them as a file.
02

Study summary

Background:

Sinonasal adenoid cystic carcinoma (ACC) is a rare type of cancer that starts in the nasal cavity or sinuses. Although surgery can remove the tumor, doctors often recommend radiation therapy after surgery to reduce the chance of the cancer coming back. However, radiation can cause long-term side effects such as bone damage, dry mouth, or difficulty opening the mouth. For patients whose tumor has been completely removed (called R0 resection) and who have early-stage disease (T1-T3) without spread to lymph nodes or other organs, it is not clear whether routine radiation therapy is always needed.

Study Objective:

This study aims to find out whether simply watching and waiting (surgery alone) is not worse than adding radiation therapy (surgery plus radiation) in terms of keeping patients free from cancer for at least 3 years. If surgery alone is shown to be as good as surgery plus radiation, some patients may be able to avoid the side effects of radiation.

Study Design:

This is a prospective, multicenter, real-world study. It is not a randomized trial - patients and their doctors will decide together whether to have radiation after surgery. We will follow about 200 patients from many hospitals across China. About half will receive surgery alone, and the other half will receive surgery followed by radiation therapy. All patients will be followed for at least 3 years.

Hypothesis:

We hypothesize that surgery alone is not inferior to surgery plus radiation therapy for 3-year disease-free survival, with a non-inferiority margin of a hazard ratio of 1.35. In other words, even if surgery alone has a slightly higher risk of cancer returning, the difference is small enough that avoiding radiation side effects may still be worthwhile.

Main Outcome:

The main outcome is the percentage of patients who are alive and free from cancer recurrence (local, regional, or distant) or death from any cause at 3 years after treatment.

Potential Impact:

If our hypothesis is confirmed, this study could change current practice. Many patients with completely resected, early-stage sinonasal ACC might safely avoid postoperative radiation and its long-term side effects, improving their quality of life without compromising cancer control.

Read the detailed description

Study Design Overview This is a prospective, multicenter, observational real-world study conducted at approximately 16 hospitals across China. Patients with completely resected (R0), T1-T3, N0M0 sinonasal adenoid cystic carcinoma (ACC) are enrolled after surgery. The study does not randomize patients; instead, treatment assignment (postoperative radiotherapy vs. observation alone) is determined by shared decision-making between the patient and the attending physician, reflecting routine clinical practice.

Treatment Groups Radiotherapy group: Patients receive intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) at a dose of 60-66 Gy to the high-risk clinical target volume (CTV1) and 54-60 Gy to the low-risk CTV2, starting within 4-6 weeks after surgery.

Observation group: Patients undergo regular follow-up without postoperative radiotherapy.

All patients receive the same standardized follow-up schedule and supportive care.

Sample Size and Power This is a prospective, multicenter observational real-world study aiming to evaluate long-term prognostic outcomes of surgery alone versus postoperative adjuvant radiotherapy among patients with R0-resected T1-T3 N0M0 sinonasal adenoid cystic carcinoma, and to perform a clinical non-inferiority assessment based on a pre-specified threshold. Based on the latest updated retrospective prognostic data from our center, the 3-year disease-free survival (DFS) rate in the postoperative radiotherapy group is 85%. A pre-specified clinical non-inferiority hazard ratio (HR) threshold of 1.35 is adopted, which represents a minimally acceptable clinical difference in the field of head-and-neck oncology. This threshold corresponds to a lower bound of 79.8% for the 3-year DFS rate in the surgery-alone group, with an anticipated true between-group effect HR of 1.35.

A two-sided significance level α of 0.05 is applied. Given the low incidence of sinonasal adenoid cystic carcinoma, the scarcity of patients within this low-risk R0-resected subgroup, and the feasibility of prospective enrolment across multiple domestic centers, the final analytical cohort will consist of 200 patients, with 100 patients in each group. This balanced cohort will be constructed via over-enrolment followed by 1:1 propensity score matching.

Statistical Methods Primary analysis: The non-inferiority of observation versus radiotherapy for 3-year DFS will be assessed using a Cox proportional hazards model with inverse probability of treatment weighting (IPTW) based on propensity scores. The non-inferiority margin is set at HR = 1.35 (upper bound of the 95% confidence interval must be \<1.35).

Propensity score model: Includes age, sex, T stage (T1/T2 vs. T3), tumor site, histologic subtype (cribriform/tubular proportion), perineural invasion, margin distance, Ki-67 index, ECOG performance status, and comorbidities.

Sensitivity analyses: Multivariable Cox regression, propensity score matching (1:1, caliper 0.2), instrumental variable analysis (using center preference as the instrument), and E-value analysis will be performed.

Secondary endpoints: Overall survival (1, 3, 5 years), 1-year and 5-year DFS, local control rate, distant metastasis rate, quality of life (EORTC QLQ-C30 and QLQ-H\&N35), and treatment-related toxicity (CTCAE v5.0) will be compared between groups using appropriate methods (Kaplan-Meier, log-rank test, or competing risk models).

Data Collection and Follow-up

Baseline data: Demographics, clinical and pathologic characteristics, surgical details.

Follow-up visits: Every 3 months for the first 2 years, every 6 months for years 3-5, and annually thereafter. Each visit includes physical examination, laboratory tests, and toxicity assessment.

Imaging: Contrast-enhanced MRI every 6 months for the first 3 years and annually for years 4-5 (or whenever clinically indicated). Chest CT annually.

All suspected recurrences are centrally reviewed by a blinded independent central review (BICR) committee using RECIST 1.1 criteria.

Quality Control and Data Monitoring

An independent Data Monitoring Committee (DMC) comprising clinical experts, biostatisticians, and ethicists will review safety data (serious adverse events) every 6 months and overall data quality annually.

Central pathology review confirms the diagnosis and histologic subtype for all enrolled patients.

Electronic data capture (EDC) with source data verification (SDV) will be used. Ethics and Dissemination

The study protocol has been approved by the Ethics Committee of the Eye \& ENT Hospital of Fudan University (approval number: 2026042-1). All participating centers will obtain local ethics approval. Written informed consent will be obtained from all patients. Results will be submitted for publication in peer-reviewed journals regardless of the outcome.

03

Conditions studied

  • Adenoid Cystic Carcinoma
  • Sinonasal Carcinoma

Keywords

  • Sinonasal Adenoid Cystic Carcinoma
  • Radiotherapy
  • Adjuvant
  • Watchful Waiting
  • Observational Study
  • Prospective Studies
  • Non-Inferiority Trials
  • Disease-Free Survival
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (age 18-75 years) with histologically confirmed cribriform or tubular type sinonasal adenoid cystic carcinoma, who have undergone R0 surgical resection and have disease staged as T1-T3, N0, M0 per AJCC 8th edition. Participants are recruited from the Department of Otolaryngology of approximately 16 tertiary hospitals across China, including the lead center (Eye \& ENT Hospital of Fudan University) and collaborating centers. Consecutive patients meeting eligibility criteria are invited to enroll after providing written informed consent. Treatment assignment (postoperative radiotherapy vs. observation alone) is determined by shared decision-making between the patient and the attending physician, reflecting routine clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years and ≤75 years.
  • confirmed adenoid cystic carcinoma of cribriform or tubular type (solid type excluded) by central pathology review.
  • Completed radical surgical resection with postoperative pathology confirming R0 resection (negative microscopic margins).
  • Tumor stage T1, T2, or T3 according to AJCC 8th edition, with N0 and M0 status.
  • Tumor originating from the nasal cavity or paranasal sinuses (excluding primary salivary gland tumors to this region).
  • performance status 0 or 1.
  • Adequate bone marrow, liver, and kidney function within 14 days before enrollment:

    • ≥1.5 × 10⁹/L, count ≥100 × 10⁹/L, ≥90 g/L.
    • Total ≤1.5 × (ULN); and ALT ≤2.5 × ULN.
    • Serum creatinine ≤1.5 × ULN or calculated ≥60 mL/min (Cockcroft-Gault formula).
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Tumor stage T4, or presence of regional lymph node (N+), or distant metastasis (M1).
  • Postoperative pathology showing positive margins (R1 or R2).
  • Prior head and neck radiotherapy.
  • Concurrent active other than adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.
  • Uncontrolled serious concomitant disease (e.g., unstable angina, recent myocardial infarction, uncontrolled hypertension).
  • Pregnant or breastfeeding women, or women of childbearing age not using effective .
  • Psychological, social, or geographic factors that may interfere with study compliance.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Surgery plus Postoperative Radiotherapy Group

    Surgery plus Postoperative Radiotherapy:Participants in this group undergo radical surgical resection of the tumor (R0 resection) followed by postoperative intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) at a dose of 60-66 Gy to the high-risk clinical target volume (CTV1) and 54-60 Gy to the low-risk CTV2. Radiotherapy is initiated within 4-6 weeks after surgery.

    Radiation: Postoperative Radiotherapy

  • Surgery Alone (Observation) Group

    No postoperative radiotherapy or any other form of adjuvant radiation. Patients undergo regular follow-up according to the study protocol, including physical examination, laboratory tests, and imaging (contrast-enhanced MRI of the head and neck every 6 months for the first 3 years and annually thereafter; chest CT annually). Active surveillance is performed to detect any recurrence or metastasis.

    Other: Observation

Interventions

  • RadiationPostoperative Radiotherapy

    Intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) delivered to the postoperative tumor bed. High-risk clinical target volume (CTV1) receives 60-66 Gy in 30-33 fractions (1.8-2.0 Gy per fraction). Low-risk clinical target volume (CTV2) receives 54-60 Gy in 30-33 fractions. Treatment starts within 4-6 weeks after surgery. Daily image guidance is used. Organs at risk are constrained according to QUANTEC/RTOG guidelines

  • OtherObservation

    No postoperative radiotherapy or any other form of adjuvant radiation. Patients undergo regular follow-up according to the study protocol, including physical examination, laboratory tests, and imaging (contrast-enhanced MRI of the head and neck every 6 months for the first 3 years and annually thereafter; chest CT annually). Active surveillance is performed to detect any recurrence or metastasis

06

What researchers measure

Primary outcomes

  1. 3-year Disease-Free Survival (DFS)

    DFS is defined as the time from enrollment to the first occurrence of any of the following events: local recurrence, regional recurrence (cervical lymph nodes), distant metastasis, or death from any cause. Patients alive and free from recurrence are censored at the last disease-free assessment. All suspected recurrences are centrally reviewed by a blinded independent central review (BICR) committee using RECIST 1.1 criteria.

    Time frame: From enrollment up to 3 years post-treatment

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from enrollment to death from any cause. Patients alive at the end of follow-up are censored at the last known alive date.

    Time frame: 1, 3, and 5 years after treatment

  2. Disease-Free Survival

    DFS is defined as the time from enrollment to first occurrence of local recurrence, regional recurrence, distant metastasis, or death from any cause. Patients alive and free from recurrence are censored at the last disease-free assessment. Same definition as primary outcome but assessed at 1-year and 5-year time points.

    Time frame: 1, and 5 years after treatment

  3. Local Control Rate (LCR)

    LCR is defined as the proportion of patients without local recurrence (at the primary tumor site) after treatment. Local recurrence is confirmed by imaging (contrast-enhanced MRI) and/or biopsy, centrally reviewed by blinded independent central review (BICR) using RECIST 1.1 criteria.

    Time frame: From enrollment up to 5 years

  4. EORTC QLQ-C30

    QoL is assessed using the Chinese versions of the EORTC QLQ-C30 (core questionnaire). Scores are calculated according to EORTC scoring manuals. Higher scores represent better functioning or worse symptoms depending on the domain.

    Time frame: Baseline, and at 6, 12, 24, and 36 months after treatment

  5. QLQ-H&N35

    QoL is assessed using the Chinese versions of the QLQ-H\&N35 (head and neck module). Scores are calculated according to EORTC scoring manuals. Higher scores represent better functioning or worse symptoms depending on the domain.

    Time frame: Baseline, and at 6, 12, 24, and 36 months after treatment

  6. Treatment-Related Toxicity

    Toxicity is graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Acute toxicity (occurring ≤90 days from start of radiotherapy or from surgery in the observation group) and late toxicity (occurring \>90 days) are recorded separately. Specific toxicities include radiation-induced osteoradionecrosis, xerostomia, trismus, pituitary dysfunction, and second primary malignancies.

    Time frame: From start of treatment up to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Akbaba S, Ahmed D, Mock A, Held T, Bahadir S, Lang K, Syed M, Hoerner-Rieber J, Forster T, Federspil P, Herfarth K, Plinkert P, Debus J, Adeberg S. Treatment Outcome of 227 Patients with Sinonasal Adenoid Cystic Carcinoma (ACC) after Intensity Modulated Radiotherapy and Active Raster-Scanning Carbon Ion Boost: A 10-Year Single-Center Experience. Cancers (Basel). 2019 Nov 1;11(11):1705. doi: 10.3390/cancers11111705. PubMed 31683896 ↗
  • Kashiwazaki R, Turner MT, Geltzeiler M, Fernandez-Miranda JC, Gardner PA, Snyderman CH, Wang EW. The endoscopic endonasal approach for sinonasal and nasopharyngeal adenoid cystic carcinoma. Laryngoscope. 2020 Jun;130(6):1414-1421. doi: 10.1002/lary.28100. Epub 2019 Jun 13. PubMed 31194275 ↗
  • Wei W, Liu JQ, Qi Y, Li XM, Meng FY, Ren QZ, Yan B, Wang ZL, Zhang QH. [Analysis of the efficacy of endoscopic transnasal surgery for sinonasal and skull base adenoid cystic carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023 May 7;58(5):438-444. doi: 10.3760/cma.j.cn115330-20221107-00666. Chinese. PubMed 37100752 ↗
  • Seong SY, Hyun DW, Kim YS, Cho HJ, Lee JG, Yoon JH, Kim CH. Treatment outcomes of sinonasal adenoid cystic carcinoma: 30 cases from a single institution. J Craniomaxillofac Surg. 2014 Jul;42(5):e171-5. doi: 10.1016/j.jcms.2013.08.002. Epub 2013 Sep 9. PubMed 24080140 ↗
  • Lupinetti AD, Roberts DB, Williams MD, Kupferman ME, Rosenthal DI, Demonte F, El-Naggar A, Weber RS, Hanna EY. Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience. Cancer. 2007 Dec 15;110(12):2726-31. doi: 10.1002/cncr.23096. PubMed 17960615 ↗
  • van Weert S, van der Waal I, Witte BI, Leemans CR, Bloemena E. Histopathological grading of adenoid cystic carcinoma of the head and neck: analysis of currently used grading systems and proposal for a simplified grading scheme. Oral Oncol. 2015 Jan;51(1):71-6. doi: 10.1016/j.oraloncology.2014.10.007. Epub 2014 Oct 28. PubMed 25456010 ↗
  • Cavalieri S, Mariani L, Vander Poorten V, Van Breda L, Cau MC, Lo Vullo S, Alfieri S, Resteghini C, Bergamini C, Orlandi E, Calareso G, Clement P, Hauben E, Platini F, Bossi P, Licitra L, Locati LD. Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. Eur J Cancer. 2020 Sep;136:35-42. doi: 10.1016/j.ejca.2020.05.013. Epub 2020 Jul 3. PubMed 32629365 ↗
  • Bjorndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen J, Kristensen CA, Homoe P, Sorensen CH, Andersen E, Bundgaard T, Primdahl H, Lambertsen K, Andersen LJ, Godballe C. Salivary gland carcinoma in Denmark 1990-2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol. 2011 Jul;47(7):677-82. doi: 10.1016/j.oraloncology.2011.04.020. Epub 2011 May 25. PubMed 21612974 ↗
  • Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol. 2006 Sep;42(8):759-69. doi: 10.1016/j.oraloncology.2006.01.001. Epub 2006 Jun 6. PubMed 16757203 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared because this is an investigator-initiated, multicenter observational real-world study. The informed consent form does not include provisions for data sharing beyond the primary research team and participating centers. Data access requests may be considered by the principal investigator upon reasonable request, but no public repository deposit is planned.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 1, 2026
StartActual
May 1, 2026
Primary completionEst.
May 1, 2029
CompletionEst.
May 1, 2032
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 3, 2026
Sites
Eye & ENT Hospital of Fudan University is now Recruiting
Nov 3, 2026
Show all 2 updates
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 3, 2026
    Not yet recruiting→Recruiting
    Eye & ENT Hospital of Fudan University is now Recruiting
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07563088
Responsible party
Quan Liu (Director of Skull Base Adenoid Cystic Carcinoma Center; Chief Physician of Otolaryngology Department, Eye & ENT Hospital of Fudan University) — Principal investigator
First posted
May 1, 2026
Start date
May 1, 2026
Primary completion
May 1, 2029 (estimated)
Completion
May 1, 2032 (estimated)
Last update
Nov 12, 2026

Study contacts

Quan Liu, MD
Contact
liuqent@163.com
+86 15001959681
Wanpeng Li, MD
Contact
18879117831@163.com
+86 13262856870

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion